Alaunos Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

TCRT$1.71+2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2023 and 2022

BALANCE SHEETS

	December 31,	December 31,
	2023	2022
ASSETS:
Current assets:
Cash and cash equivalents	$6,062	$39,058
Restricted cash	—	13,938
Receivables	1	4
Prepaid expenses and other current assets	2,198	799
Total current assets	8,261	53,799
Property and equipment, net	2	8,460
Right-of-use assets	—	2,136
Deposits	—	42
Other non-current assets	—	500
Total assets	$8,263	$64,937
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$616	$1,389
Current portion of long-term debt	—	16,765
Accrued expenses	1,340	5,454
Lease liabilities, current	—	558
Total current liabilities	1,956	24,166
Lease liabilities, non-current	—	2,188
Other non-current liabilities	—	28
Total liabilities	$1,956	$26,382
Commitments and contingencies (Note 9)
Stockholders' equity
Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at December 31, 2023 and 28,000,000 shares authorized, 16,027,384 shares issued and outstanding at December 31, 2022	16	16
Additional paid-in capital	922,058	919,166
Accumulated deficit	(915,767)	(880,627)
Total stockholders' equity	6,307	38,555
Total liabilities and stockholders' equity	$8,263	$64,937

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.